Please login to the form below

Not currently logged in
Email:
Password:

MPDL3280A

This page shows the latest MPDL3280A news and features for those working in and with pharma, biotech and healthcare.

Roche gets first approval for PD-L1 inhibitor Tecentriq

Roche gets first approval for PD-L1 inhibitor Tecentriq

Specifically, the FDA has approved atezolizumab (MPDL3280A) - which will be sold as Tecentriq - for people with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed during or after

Latest news

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Roche sees the potential to combine these therapies with other immunotherapies already in its oncology portfolio, such as MPDL3280A, which targets the PD-L1 receptor on cancer cells.  .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics